Sign in with Google. Opens in new tab
bullish
Pharmaessentia Corp (6446 TT): Third Consecutive Quarters for Operating Profit; Pipeline Raises Hope
660 Views20 Nov 2024 01:30
Boomeranged on Mon, 6 Jan 2025 05:30
Pharmaessentia has announced positive topline results from phase 3 clinical trial of P1101 for Essential Thrombocythemia (ET) with statistical significance achieved for the primary and secondary endpoints. The company expects to file marketing application for P1101 by the end of 2025. Indication expansion of P1101 in ET will almost double the target patient population size in the U.S.
SUMMARY
- Pharmaessentia Corp (6446 TT) reported 66% QoQ increase in operating profit in 3Q24. Scale expansion coupled with tight control over expenses led to such strong performance.
- 3Q24 marks the six consecutive quarters of sequential revenue increase. Revenue for the first three quarters of 2024 already exceeded full-year 2023 revenue.
- Geography expansion of the sole marketed drug Besremi, indication expansion, and pipeline progress will remain the main growth engines. Pharmaessentia is eyeing on Besremi’s indication expansion in US by 2026.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Hygon/Sugon Merger: BIG Index Flows on Completion
- Why Is LG CNS One of the Hottest Stocks in Korea in the Past One Month? Answer: Stablecoin Platform
- Toyota Motor (7203 JP) Tactical Outlook: Uncertainty Persists, But Rebound Likely
- Ohayo Japan | Limited Retaliation to U.S. Strikes
- Virgin Australia IPO Trading - Flying into Oil and Recent Air Crash Headwinds
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Pharmaessentia Corp (6446 TT): Strong Start of 2025; Growth Momentum to Continue05 Jun 2025
- Pharmaessentia Corp (6446 TT): Arbitration Reaction Is Overdone; Time to Re-Focus on Fundamentals03 Apr 2025
- Pharmaessentia Corp (6446 TT): Third Consecutive Quarters for Operating Profit; Pipeline Raises Hope20 Nov 2024
- Pharmaessentia Corp (6446 TT): Starts 2024 on Strong Note; Reports First Operating Profit in 1Q2425 Jun 2024
- Pharmaessentia Corp (6446 TT): Readying for Next Growth Phase with Besremi’s Continued Traction07 Mar 2024
- Pharmaessentia Corp (6446 TT): Besremi Revenue Is Recovering; Fund Raising Through GDS Completed21 Jul 2023
x